

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Age at Screening (Years)									
n	11415	11414	22830	3750	3770	7520	15165	15184	30350
Mean	45.0	45.1	45.0	70.8	70.4	70.6	51.3	51.4	51.4
(SD)	(12.30)	(12.35)	(12.32)	(4.88)	(4.66)	(4.77)	(15.60)	(15.50)	(15.55)
Median	46.0	46.0	46.0	70.0	69.0	70.0	52.0	53.0	52.0
Min, Max	18, 64	18, 64	18, 64	65, 95	65, 95	65, 95	18, 95	18, 95	18, 95
Age Group at Screening, n (%)									
>=18 and <65 Years	11415 (100)	11414 (100)	22830 (100)	0	0	0	11415 (75.3)	11414 (75.2)	22830 (75.2)
Mean	45.0	45.1	45.0				45.0	45.1	45.0
(SD)	(12.30)	(12.35)	(12.32)				(12.30)	(12.35)	(12.32)
Median	46.0	46.0	46.0				46.0	46.0	46.0
Min, Max	18, 64	18, 64	18, 64				18, 64	18, 64	18, 64
>=65 Years	0	0	0	3750 (100)	3770 (100)	7520 (100)	3750 (24.7)	3770 (24.8)	7520 (24.8)
Mean				70.8	70.4	70.6	70.8	70.4	70.6
(SD)				(4.88)	(4.66)	(4.77)	(4.88)	(4.66)	(4.77)
Median				70.0	69.0	70.0	70.0	69.0	70.0
Min, Max				65, 95	65, 95	65, 95	65, 95	65, 95	65, 95

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Age Subgroup at Screening, n (%)									
>=18 and <65 Years	11415 (100)	11414 (100)	22830 (100)	0	0	0	11415 (75.3)	11414 (75.2)	22830 (75.2)
>=65 and <70 Years	0	0	0	1816 (48.4)	1906 (50.6)	3722 (49.5)	1816 (12.0)	1906 (12.6)	3722 (12.3)
>=70 and <75 Years	0	0	0	1193 (31.8)	1205 (32.0)	2398 (31.9)	1193 (7.9)	1205 (7.9)	2398 (7.9)
>=75 and <80 Years	0	0	0	507 (13.5)	468 (12.4)	975 (13.0)	507 (3.3)	468 (3.1)	975 (3.2)
>=80 Years	0	0	0	234 (6.2)	191 (5.1)	425 (5.7)	234 (1.5)	191 (1.3)	425 (1.4)
Age Subgroup at Screening, n (%)									
>=18 and <65 Years	11415 (100)	11414 (100)	22830 (100)	0	0	0	11415 (75.3)	11414 (75.2)	22830 (75.2)
>=65 and <75 Years	0	0	0	3009 (80.2)	3111 (82.5)	6120 (81.4)	3009 (19.8)	3111 (20.5)	6120 (20.2)
>=75 and <85 Years	0	0	0	692 (18.5)	618 (16.4)	1310 (17.4)	692 (4.6)	618 (4.1)	1310 (4.3)
>=85 Years	0	0	0	49 (1.3)	41 (1.1)	90 (1.2)	49 (0.3)	41 (0.3)	90 (0.3)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Age and Health Risk for Severe COVID-19, n (%) [1]									
>=18 and <65 Years and Not at Risk	8883 (77.8)	8889 (77.9)	17772 (77.8)	1 (<0.1)	0	1 (<0.1)	8884 (58.6)	8889 (58.5)	17773 (58.6)
>=18 and <65 Years and at Risk	2531 (22.2)	2524 (22.1)	5056 (22.1)	3 (<0.1)	6 (0.2)	9 (0.1)	2534 (16.7)	2530 (16.7)	5065 (16.7)
>=65 Years	1 (<0.1)	1 (<0.1)	2 (<0.1)	3746 (99.9)	3764 (99.8)	7510 (99.9)	3747 (24.7)	3765 (24.8)	7512 (24.8)
Risk Factor for Severe COVID-19 at Screening, n (%) [2]									
Chronic Lung Disease	500 (4.4)	471 (4.1)	971 (4.3)	241 (6.4)	236 (6.3)	477 (6.3)	741 (4.9)	707 (4.7)	1448 (4.8)
Significant Cardiac Disease	296 (2.6)	310 (2.7)	606 (2.7)	445 (11.9)	432 (11.5)	877 (11.7)	741 (4.9)	742 (4.9)	1483 (4.9)
Severe Obesity	855 (7.5)	846 (7.4)	1701 (7.5)	123 (3.3)	140 (3.7)	263 (3.5)	978 (6.4)	986 (6.5)	1964 (6.5)
Diabetes	897 (7.9)	900 (7.9)	1797 (7.9)	534 (14.2)	527 (14.0)	1061 (14.1)	1431 (9.4)	1427 (9.4)	2858 (9.4)
Liver Disease	70 (0.6)	82 (0.7)	152 (0.7)	26 (0.7)	18 (0.5)	44 (0.6)	96 (0.6)	100 (0.7)	196 (0.6)
Human Immunodeficiency Virus Infection	72 (0.6)	75 (0.7)	147 (0.6)	14 (0.4)	15 (0.4)	29 (0.4)	86 (0.6)	90 (0.6)	176 (0.6)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
At Risk for Severe COVID-19 at Screening, n (%)									
Yes	2283 (20.0)	2275 (19.9)	4558 (20.0)	1099 (29.3)	1085 (28.8)	2184 (29.0)	3382 (22.3)	3360 (22.1)	6742 (22.2)
One Risk Factor for Severe COVID-19	1925 (16.9)	1919 (16.8)	3844 (16.8)	854 (22.8)	839 (22.3)	1693 (22.5)	2779 (18.3)	2758 (18.2)	5537 (18.2)
Two or More Risk Factors for Severe COVID-19	358 (3.1)	356 (3.1)	714 (3.1)	245 (6.5)	246 (6.5)	491 (6.5)	603 (4.0)	602 (4.0)	1205 (4.0)
No	9132 (80.0)	9139 (80.1)	18272 (80.0)	2651 (70.7)	2685 (71.2)	5336 (71.0)	11783 (77.7)	11824 (77.9)	23608 (77.8)
Age and Risk for Severe COVID-19, n (%) [3]									
>=18 and <65 Years and Not at Risk	9132 (80.0)	9139 (80.1)	18272 (80.0)	0	0	0	9132 (60.2)	9139 (60.2)	18272 (60.2)
>=18 and <65 Years and at Risk	2283 (20.0)	2275 (19.9)	4558 (20.0)	0	0	0	2283 (15.1)	2275 (15.0)	4558 (15.0)
>=65 Years and Not at Risk	0	0	0	2651 (70.7)	2685 (71.2)	5336 (71.0)	2651 (17.5)	2685 (17.7)	5336 (17.6)
>=65 Years and at Risk	0	0	0	1099 (29.3)	1085 (28.8)	2184 (29.0)	1099 (7.2)	1085 (7.1)	2184 (7.2)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Baseline RT-PCR Results, n (%)									
Negative	11189 (98.0)	11174 (97.9)	22364 (98.0)	3686 (98.3)	3709 (98.4)	7395 (98.3)	14875 (98.1)	14883 (98.0)	29759 (98.1)
Positive	85 (0.7)	80 (0.7)	165 (0.7)	10 (0.3)	7 (0.2)	17 (0.2)	95 (0.6)	87 (0.6)	182 (0.6)
Missing	141 (1.2)	160 (1.4)	301 (1.3)	54 (1.4)	54 (1.4)	108 (1.4)	195 (1.3)	214 (1.4)	409 (1.3)
Baseline Elecsys Anti-SARS-CoV-2 Results, n (%)									
Negative	10876 (95.3)	10830 (94.9)	21706 (95.1)	3630 (96.8)	3637 (96.5)	7267 (96.6)	14506 (95.7)	14467 (95.3)	28973 (95.5)
Positive	271 (2.4)	271 (2.4)	542 (2.4)	28 (0.7)	32 (0.8)	60 (0.8)	299 (2.0)	303 (2.0)	602 (2.0)
Missing	268 (2.3)	313 (2.7)	582 (2.5)	92 (2.5)	101 (2.7)	193 (2.6)	360 (2.4)	414 (2.7)	775 (2.6)
Baseline SARS-CoV-2 Status, n (%) [4]									
Negative	10771 (94.4)	10712 (93.8)	21483 (94.1)	3595 (95.9)	3604 (95.6)	7199 (95.7)	14366 (94.7)	14316 (94.3)	28682 (94.5)
Positive	301 (2.6)	306 (2.7)	607 (2.7)	33 (0.9)	35 (0.9)	68 (0.9)	334 (2.2)	341 (2.2)	675 (2.2)
Missing	343 (3.0)	396 (3.5)	740 (3.2)	122 (3.3)	131 (3.5)	253 (3.4)	465 (3.1)	527 (3.5)	993 (3.3)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Sex, n (%)									
Male	5961 (52.2)	5850 (51.3)	11812 (51.7)	2104 (56.1)	2079 (55.1)	4183 (55.6)	8065 (53.2)	7929 (52.2)	15995 (52.7)
Female	5454 (47.8)	5564 (48.7)	11018 (48.3)	1646 (43.9)	1691 (44.9)	3337 (44.4)	7100 (46.8)	7255 (47.8)	14355 (47.3)
Race, n (%)									
White	8651 (75.8)	8653 (75.8)	17305 (75.8)	3339 (89.0)	3379 (89.6)	6718 (89.3)	11990 (79.1)	12032 (79.2)	24023 (79.2)
Black or African American	1314 (11.5)	1341 (11.7)	2655 (11.6)	214 (5.7)	221 (5.9)	435 (5.8)	1528 (10.1)	1562 (10.3)	3090 (10.2)
Asian	655 (5.7)	587 (5.1)	1242 (5.4)	77 (2.1)	66 (1.8)	143 (1.9)	732 (4.8)	653 (4.3)	1385 (4.6)
American Indian or Alaska Native	94 (0.8)	89 (0.8)	183 (0.8)	26 (0.7)	21 (0.6)	47 (0.6)	120 (0.8)	110 (0.7)	230 (0.8)
Native Hawaiian or Other Pacific Islander	29 (0.3)	31 (0.3)	60 (0.3)	3 (<0.1)	3 (<0.1)	6 (<0.1)	32 (0.2)	34 (0.2)	66 (0.2)
Multiracial	281 (2.5)	281 (2.5)	562 (2.5)	38 (1.0)	34 (0.9)	72 (1.0)	319 (2.1)	315 (2.1)	634 (2.1)
Other	283 (2.5)	294 (2.6)	577 (2.5)	32 (0.9)	27 (0.7)	59 (0.8)	315 (2.1)	321 (2.1)	636 (2.1)
Not Reported	62 (0.5)	86 (0.8)	148 (0.6)	13 (0.3)	13 (0.3)	26 (0.3)	75 (0.5)	99 (0.7)	174 (0.6)
Unknown	46 (0.4)	52 (0.5)	98 (0.4)	8 (0.2)	6 (0.2)	14 (0.2)	54 (0.4)	58 (0.4)	112 (0.4)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Ethnicity, n (%)									
Hispanic or Latino	2777 (24.3)	2766 (24.2)	5544 (24.3)	335 (8.9)	355 (9.4)	690 (9.2)	3112 (20.5)	3121 (20.6)	6234 (20.5)
Not Hispanic or Latino	8541 (74.8)	8549 (74.9)	17090 (74.9)	3373 (89.9)	3371 (89.4)	6744 (89.7)	11914 (78.6)	11920 (78.5)	23834 (78.5)
Not Reported	58 (0.5)	72 (0.6)	130 (0.6)	26 (0.7)	32 (0.8)	58 (0.8)	84 (0.6)	104 (0.7)	188 (0.6)
Unknown	39 (0.3)	27 (0.2)	66 (0.3)	16 (0.4)	12 (0.3)	28 (0.4)	55 (0.4)	39 (0.3)	94 (0.3)
Race and Ethnicity Group, n (%)									
[5]									
Minority	4070 (35.7)	4066 (35.6)	8137 (35.6)	560 (14.9)	579 (15.4)	1139 (15.1)	4630 (30.5)	4645 (30.6)	9276 (30.6)
Non-minority	7331 (64.2)	7328 (64.2)	14659 (64.2)	3177 (84.7)	3185 (84.5)	6362 (84.6)	10508 (69.3)	10513 (69.2)	21021 (69.3)
Missing	14 (0.1)	20 (0.2)	34 (0.1)	13 (0.3)	6 (0.2)	19 (0.3)	27 (0.2)	26 (0.2)	53 (0.2)
Race and Ethnicity Group, n (%)									
[6]									
White	6396 (56.0)	6461 (56.6)	12857 (56.3)	3062 (81.7)	3073 (81.5)	6135 (81.6)	9458 (62.4)	9534 (62.8)	18992 (62.6)
Communities of Color	5005 (43.8)	4933 (43.2)	9939 (43.5)	675 (18.0)	691 (18.3)	1366 (18.2)	5680 (37.5)	5624 (37.0)	11305 (37.2)
Missing	14 (0.1)	20 (0.2)	34 (0.1)	13 (0.3)	6 (0.2)	19 (0.3)	27 (0.2)	26 (0.2)	53 (0.2)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Weight (kg)									
n	11253	11242	22495	3700	3710	7410	14953	14952	29905
Mean	86.73	86.52	86.63	83.17	83.13	83.15	85.85	85.68	85.76
(SD)	(22.398)	(22.695)	(22.547)	(18.907)	(19.447)	(19.178)	(21.641)	(21.982)	(21.812)
Median	83.64	83.64	83.64	81.60	81.21	81.36	83.00	83.00	83.00
Min, Max	3.5, 223.0	30.3, 236.4	3.5, 236.4	34.8, 184.5	31.5, 168.6	31.5, 184.5	3.5, 223.0	30.3, 236.4	3.5, 236.4
Height (cm)									
n	11253	11241	22494	3700	3711	7411	14953	14952	29905
Mean	171.16	170.96	171.06	170.06	169.94	170.00	170.89	170.71	170.80
(SD)	(9.999)	(9.895)	(9.948)	(10.231)	(10.018)	(10.124)	(10.068)	(9.935)	(10.002)
Median	171.00	170.18	170.50	170.18	170.18	170.18	170.50	170.18	170.20
Min, Max	110.6, 205.7	104.1, 208.5	104.1, 208.5	124.5, 223.5	123.0, 208.3	123.0, 223.5	110.6, 223.5	104.1, 208.5	104.1, 223.5
Body Mass Index (kg/m ²)									
n	11252	11238	22490	3699	3710	7409	14951	14948	29899
Mean	29.52	29.53	29.53	28.69	28.69	28.69	29.32	29.32	29.32
(SD)	(6.956)	(7.135)	(7.046)	(5.857)	(5.931)	(5.894)	(6.710)	(6.865)	(6.788)
Median	28.27	28.25	28.26	27.71	27.85	27.78	28.12	28.12	28.12
Min, Max	1.5, 87.3	10.5, 86.1	1.5, 87.3	12.1, 71.1	11.2, 66.7	11.2, 71.1	1.5, 87.3	10.5, 86.1	1.5, 87.3

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Occupational Risk, n (%) [2]	10109 (88.6)	10060 (88.1)	20169 (88.3)	2378 (63.4)	2360 (62.6)	4738 (63.0)	12487 (82.3)	12420 (81.8)	24907 (82.1)
Healthcare Workers	3323 (29.1)	3325 (29.1)	6648 (29.1)	503 (13.4)	462 (12.3)	965 (12.8)	3826 (25.2)	3787 (24.9)	7613 (25.1)
Emergency Response	278 (2.4)	282 (2.5)	560 (2.5)	19 (0.5)	21 (0.6)	40 (0.5)	297 (2.0)	303 (2.0)	600 (2.0)
Retail or Restaurant Operations	871 (7.6)	855 (7.5)	1726 (7.6)	99 (2.6)	100 (2.7)	199 (2.6)	970 (6.4)	955 (6.3)	1925 (6.3)
Manufacturing and Production Operations	390 (3.4)	392 (3.4)	782 (3.4)	30 (0.8)	34 (0.9)	64 (0.9)	420 (2.8)	426 (2.8)	846 (2.8)
Warehouse Shipping and Fulfillment Centers	162 (1.4)	184 (1.6)	346 (1.5)	12 (0.3)	9 (0.2)	21 (0.3)	174 (1.1)	193 (1.3)	367 (1.2)
Transportation and Delivery Services	412 (3.6)	435 (3.8)	847 (3.7)	61 (1.6)	50 (1.3)	111 (1.5)	473 (3.1)	485 (3.2)	958 (3.2)
Border Protection and Military Personnel	62 (0.5)	66 (0.6)	128 (0.6)	6 (0.2)	3 (<0.1)	9 (0.1)	68 (0.4)	69 (0.5)	137 (0.5)
Personal Care and In-Home Services	409 (3.6)	402 (3.5)	811 (3.6)	61 (1.6)	67 (1.8)	128 (1.7)	470 (3.1)	469 (3.1)	939 (3.1)
Hospitality and Tourism Workers	189 (1.7)	202 (1.8)	391 (1.7)	44 (1.2)	36 (1.0)	80 (1.1)	233 (1.5)	238 (1.6)	471 (1.6)
Pastoral, Social or Public Health Workers	362 (3.2)	387 (3.4)	749 (3.3)	139 (3.7)	148 (3.9)	287 (3.8)	501 (3.3)	535 (3.5)	1036 (3.4)
Educators and Students	1377 (12.1)	1356 (11.9)	2733 (12.0)	169 (4.5)	184 (4.9)	353 (4.7)	1546 (10.2)	1540 (10.1)	3086 (10.2)
Other	3375 (29.6)	3380 (29.6)	6755 (29.6)	1422 (37.9)	1427 (37.9)	2849 (37.9)	4797 (31.6)	4807 (31.7)	9604 (31.6)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

	>=18 and <65 Years			>=65 Years			Overall		
	Placebo (N=11415)	mRNA-1273 (N=11414)	Total (N=22830)	Placebo (N=3750)	mRNA-1273 (N=3770)	Total (N=7520)	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Location and Living	9484	9490	18974	3085	3113	6198	12569	12603	25172
Circumstances Risk, n (%) [2]	(83.1)	(83.1)	(83.1)	(82.3)	(82.6)	(82.4)	(82.9)	(83.0)	(82.9)
Resides in Nursing Home or	9	22	31	20	11	31	29	33	62
Assisted Living Facility	(<0.1)	(0.2)	(0.1)	(0.5)	(0.3)	(0.4)	(0.2)	(0.2)	(0.2)
Resides in Multi-Family	345	396	741	63	66	129	408	462	870
Dwelling	(3.0)	(3.5)	(3.2)	(1.7)	(1.8)	(1.7)	(2.7)	(3.0)	(2.9)
Resides in High Density	1064	1031	2095	240	251	491	1304	1282	2586
Housing	(9.3)	(9.0)	(9.2)	(6.4)	(6.7)	(6.5)	(8.6)	(8.4)	(8.5)
Resides in Low Density,	1221	1228	2449	254	242	496	1475	1470	2945
Multi-Family Setting	(10.7)	(10.8)	(10.7)	(6.8)	(6.4)	(6.6)	(9.7)	(9.7)	(9.7)
Resides in a Single Family	6070	6027	12097	2237	2265	4502	8307	8292	16599
Home	(53.2)	(52.8)	(53.0)	(59.7)	(60.1)	(59.9)	(54.8)	(54.6)	(54.7)
Other	1636	1638	3274	529	547	1076	2165	2185	4350
	(14.3)	(14.4)	(14.3)	(14.1)	(14.5)	(14.3)	(14.3)	(14.4)	(14.3)

Note: Footnotes are listed on the last page.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\FDA\TLF\t1401030202.sas 02DEC2020 09:46

Table 14.1.3.2.2
Baseline Demographics and Characteristics by Age Group
Safety Set

Percentages are based on the number of safety subjects.

- [1] Based on stratification factor from IRT, subjects who are < 65 years old are categorized as at risk for severe COVID-19 illness if they have at least 1 of the risk factors specified in the study protocol at Screening.
- [2] Subjects could be under one or more categories, and are counted once at each category.
- [3] Age and health risk for severe COVID-19 are derived from age and risk factors collected on case report form (CRF).
- [4] Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.
- [5] Minority is defined as: Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders, and Non-Minority includes all the others whose race or ethnicity is not unknown, unreported or missing.
- [6] White is defined as White and non-Hispanic, and Communities of Color includes all the others whose race or ethnicity is not unknown, unreported or missing.